Antares Pharma, a Ewing-based specialty pharmaceutical company, has named a new chief medical officer, it announced Monday.
The company said in a news release that Dr. Peter Richardson has been named executive vice president, research & development, as well as chief medical officer. In his new role, Richardson will oversee the company’s R&D programs, including ideation, formulation and more.
“Peter brings a wealth of experience and expertise in multiple therapeutic areas, including endocrinology and product development, to the organization,” Robert F. Apple, CEO and president, said in a prepared statement. “As we remain focused on advancing our proprietary pipeline with ATRS-1901, a urology-oncology auto-injector product, and ATRS-1902, an endocrinology rescue pen, we believe his career in the pharmaceutical industry and proven track record will support our continued success and further enhance the opportunities around our portfolio and technology.”
Richardson, who has more than 25 years of R&D experience in the pharma and medical device industries, most recently was chief medical officer for Adare Pharmaceuticals and vice president of R&D and president, Adare Pharmaceuticals US, before Adare was acquired last year.
“I am delighted to join Antares at this juncture of their growth and development,” he said in a statement. “I am impressed by the success they have already garnered in their proprietary and partnered business, and I look forward to working with an exceptional organization that remains dedicated to product development.”
